Mersana slapped with partial FDA hold after five patient deaths in ovarian cancer studies
Another one of Mersana’s clinical programs is reporting patient deaths in a study, and now it’s prompting the FDA to step in.
The agency slapped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
